StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3086% above fair value
$7.48−0.05 (-0.66%)

Close on Nov 18, 2026Market cap $3.39BP/E –Yield –

Iovance Biotherapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Iovance Biotherapeutics's gross margin for the twelve months ending Jun 30, 2026 was 48.4%. For fiscal 2025 it was 34.3%, against 43.2% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202534.3%−8.9
FY2024Dec 31, 202443.2%+30.0
FY2023Dec 31, 202313.1%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202656.1%+37.6
Q1 FY2026Mar 31, 202640.5%+27.1
Q4 FY2025Dec 31, 202550.3%+1.6
Q3 FY2025Sep 30, 202543.0%−3.2
Q2 FY2025Jun 30, 202518.5%+19.3
Q1 FY2025Mar 31, 202513.4%+928.9
Q4 FY2024Dec 31, 202448.7%+854.3
Q3 FY2024Sep 30, 202446.2%+871.5
Q2 FY2024Jun 30, 2024-0.8%+760.5
Q1 FY2024Mar 31, 2024-915.5%–
Q4 FY2023Dec 31, 2023-805.6%–
Q3 FY2023Sep 30, 2023-825.4%–
Q2 FY2023Jun 30, 2023-761.3%–

More Iovance Biotherapeutics figures

See a number that looks wrong?